Tioga Pharmaceuticals

Tioga Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing innovative therapies for pruritus and gastrointestinal diseases. The company's lead product, Asimadoline, is an orally active kappa opioid receptor agonist that targets itching associated with atopic dermatitis and also addresses gastrointestinal conditions such as irritable bowel syndrome and functional dyspepsia. Founded in 2005, Tioga aims to provide effective treatments that offer safety benefits by minimizing typical opioid side effects, thus enhancing patient outcomes in managing these conditions.